Saúde Pública/Medicina Humanitária
Série de casos | Achados clínicos e de ressonância magnética em 4 casos de miocardite após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 10:58hComentário: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology
Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Série de casos | Miocardite sintomática aguda em 7 adolescentes após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 10:57hRelacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
De acordo com um novo relatório, quase 25% dos pacientes que tiveram COVID-19 desenvolvem sintomas de longa duração.
16 Jun, 2021 | 10:55hAlmost 25% of COVID-19 Patients Develop Long-Lasting Symptoms, According to a New Report – TIME
Relatório original: A Detailed Study of Patients with Long-Haul COVID – FAIR Health
Comentário no Twitter (fio – clique para saber mais)
📍1 in 4–almost a quarter of people infected develop at least one lingering health problem after 30 days with #COVID19. The most common included pain, breathing trouble, high cholesterol, malaise and/or fatigue and high blood pressure. 🧵 https://t.co/G4uPtnq86A
— Eric Feigl-Ding (@DrEricDing) June 15, 2021
M-A | Distribuição do período de incubação da Covid-19 – “O período médio de incubação da COVID-19 foi de 5,2 a 7,2 dias, e o percentil 95 estaria entre 11 e 14,6 dias.”
16 Jun, 2021 | 10:53hPerspectiva de longo prazo sobre a imunidade à COVID – “Estudos clínicos agora indicam que a imunidade é de longa duração.”
16 Jun, 2021 | 10:52hA long-term perspective on immunity to COVID – Nature
França recomenda dose única de vacina caso uma infecção prévia por Covid seja detectada.
16 Jun, 2021 | 10:51hFrance recommends single dose of vaccine if previous Covid infection detected – Rfi
Relacionado: [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. E Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
Série BMJ | O futuro da enfermagem.
16 Jun, 2021 | 10:48hPágina principal: The future of nursing – The BMJ
How to reposition the nursing profession for a post-covid age
How the nursing profession should adapt for a digital future
How to attain gender equality in nursing—an essay
Nursing’s pivotal role in global climate action
Estudo randomizado | Breve aconselhamento + amostra grátis de reposição de nicotina + referenciamento ativo quase que dobram as chances de abandono do tabagismo entre pais fumantes.
16 Jun, 2021 | 10:46hBrief Advice, Nicotine Replacement Therapy Sampling, and Active Referral for Expectant Fathers Who Smoke Cigarettes: A Randomized Clinical Trial – JAMA Internal Medicine (gratuito por tempo limitado)
Revisão | Check-ups na atenção primária ao adulto.
16 Jun, 2021 | 10:44hGeneral Health Checks in Adult Primary Care: A Review – JAMA (gratuito por tempo limitado)
Editorial: The Routine General Medical Checkup: Valuable Practice or Unnecessary Ritual? – JAMA
Podcast: General Health Checks in Adult Primary Care
[Comunicado de imprensa – Ainda não publicado] Vacina da Novavax contra COVID-19 demonstra 90% de eficácia geral e 100% de proteção contra doença moderada e grave.
15 Jun, 2021 | 11:35hComunicado de imprensa: Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Comentários: U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 – NIH News Releases E Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show – STAT E Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply – Science E Novavax COVID vaccine 90% effective in phase 3 trial – CIDRAP E What the Novavax vaccine means for the global fight against Covid-19 – Vox
Comentário no Twitter (fio – clique para saber mais)
Good news—Novavax protein-subunit vaccine phase 3 trial shown to to be 90.4% effective overall, 100% against moderate to severe disease. This is different type from mRNA and from AZ/J&J adenovirus vaccines, and different from inactivated types. #COVID19 https://t.co/ajoGhaOUu9
— Eric Feigl-Ding (@DrEricDing) June 14, 2021